Nachrichten zur Cytokinetics Inc. Aktie

Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

CYTK reports narrower-than-expected Q1 loss. However, the target action date for aficamten in obstructive HCM has been extended by the…

Cytokinetics: Strong Buy As FDAs 3-Month Delay Doesnt Derail Aficamtens Approval Outlook

…

Cytokinetics, Incorporated (CYTK) Q1 2025 Earnings Call Transcript

…

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of 3.55% and 26.49%, respectively, for the quarter ended March 2025. Do the…

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might…

Cytokinetics: Derisked PDUFA Ahead, But Commercial Success Is The Question

…

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon…

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -3.28% and 14.21%, respectively, for the quarter ended December 2024. Do the…

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release

Cytokinetics (CYTK) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Cytokinetics jumps amid renewed takeover speculation

…

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart…

Stifel starts Cytokinetics stock with Buy, $80 target By Investing.com

Stifel starts Cytokinetics stock with Buy, $80 target…

Why Cytokinetics Stock Was a Nearly 5% Winner Today

California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by…

Cytokinetics stock rises on Sanofis rights acquisition By Investing.com

Cytokinetics stock rises on Sanofis rights acquisition…

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will…

Bayer: 560-Millionen-Euro-Deal für Herz-Kreislauf-Markt

Bayer hat eine exklusive Lizenzvereinbarung mit Cytokinetics für das Herzmedikament Aficamten abgeschlossen, das gegen hypertrophe Kardiomyopathie (HCM) eingesetzt wird. Der…

Bayer: Spannender Deal in Japan – die Details

Der DAX-Konzern Bayer stärkt sein Pharma-Portfolio. Mit dem US-Biotechnologie-Unternehmen Cytokinetics konnten die Leverkusener eine exklusive Lizenzvereinbarung für Aficamten in Japan…

Bayer: Spannender Deal in Japan – die Details

Der DAX-Konzern Bayer stärkt sein Pharma-Portfolio. Mit dem US-Biotechnologie-Unternehmen Cytokinetics konnten die Leverkusener eine exklusive Lizenzvereinbarung für Aficamten in Japan…